soul trial oral semaglutide cardiovascular outcomes 2024 results mace Reduces CV Events in T2DM โ (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine ๐งช T2DM + ASCVD/CKD ๐ Oral semaglutide 14 mg vs placebo ๐ Frontiers | Effects of subcutaneous
Description
Ivy Shi et al have mapped out an elegant estimate of how many people in the U.S
This makes it a triple agonist medication, the first of its kind
March 2, 2026
Wir erklren dir, wie das funktioniert - und welche Nhrstoffe dich unbedingt begleiten sollten.
Non-obese diabetic mice aged 7 weeks were treated for 1 week with JD-5037, then euthanised
